ScheBo® • Elastase 1 – Canine - Pet Enjoy Bio-Science Co., Ltd.

ScheBo® • Elastase 1 – Canine

  • Non-radioactive pancreatic function test for dogs

    • Non-radioactive pancreatic function test for dogs!
    • Weight Loss – Maldigestion in dogs !
    • Is the pancreas involved?
    • Weight loss and maldigestion (usually presenting as steatorrhoea) are two of the main clinical symptoms suggestive of pancreatic exocrine insufficiency in dogs. A diagnosis or exclusion of this condition is then required.
    • Exocrine pancreatic insufficiency is very often only diagnosed as a reason for weight loss, maldigestion and /or steatorrhoea at an advanced stage of disease. However, an early diagnosis of exocrine pancreatic insufficiency allows early initiation of successful treatment with pancreatic enzymes substitution therapy.
    • Reference:
    • ScheBo® • Elastase 1- Canine is a non-radioactive and highly sensitive and specific assay for the determination of canine pancreatic elastase 1 (E1) in faeces, which reflects the exocrine capacity of the pancreas.
    • ScheBo® • Elastase 1- Canine is an ELISA test based on monoclonal antibodies and guarantees a reliable diagnosis of exocrine pancreatic insufficiency even under pancreatic enzyme substitution therapy. Using this test exocrine pancreatic insufficiency can be distinguished from intestinal diseases and hepatobiliary disorders affecting the small intestine.

    Indications and main advantages

    • Diagnosis or exclusion of exocrine pancreatic insufficiency caused by, for example, pancreatic acinar atrophy, pancreatic cancer, chronic pancreatitis, parasites or stones.
    • E1 is absolutely pancreas-specific.
    • The test is non-radioactive. An isotopic laboratory is not required.
    • A single pea-sized stool sample is sufficient.
    • High stability of pancreatic elastase 1 allows time for convenient mailing.
    • No need to interrupt substitution therapy.
    • There is no need for a 12-hour starvation period, in contrast to the necessary preparation before the cTLI test.

    General information

    The first test for the quantification of canine faecal elastase 1 indicated in suspicion of pancreatic exocrine insufficiency.

    The pancreas of dogs secretes a digestive enzyme that is homologous to human pancreatic elastase 1. Canine pancreatic elastase 1 (E1) remains undegraded during intestinal transit. Therefore its faecal concentration reflects pancreatic exocrine function.

    To improve the diagnosis of canine pancreatic exocrine insufficiency ScheBo® • Biotech has developed a species-specific enzyme immunoassay (ELISA) that allows quantification of pancreatic elastase1 in the faeces of dogs. This ELISA is based on canine-specific monoclonal antibodies and allows diagnosis or exclusion of pancreatic exocrine insufficiency in dogs, which is mainly due to pancreatic acinar atrophy, chronic pancreatitis or the disturbed flow of pancreatic juice.

    Quantification of human pancreatic elastase 1 in faeces has proven to be a superior non-invasive pancreatic function test for the diagnosis of pancreatic exocrine insufficiency with a sensitivity and specificity of 93%. Its results correlate well with the invasive gold standard secretin-pancreozymin test. The ScheBo® • Elastase 1 – Canine test promises to deliver similar reliability in measuring canine exocrine function.

    Veterinary diagnostic- ELISA Test

    Indications, advantages, reference concentration, specificity and sensitivity, method of detection, sample material, short protocoll.

    Indications

    Diagnosis or exclusion of exocrine pancreatic insufficiency caused by, for example, pancreatic acinar atrophy, pancreatic tumor, chronic pancreatitis, parasites or stones.

    Advantages

    In contrast to conventional laboratory parameters of canine pancreatic exocrine function, the determination of pancreatic elastase 1 has the following advantages:

    • The test is non-radioactive. An isotopic laboratory is not required.
    • In contrast to the cTLI test, canine elastase 1 measurement has the advantage that acute inflammatory episodes do not result in false normal values.
    • E1 is absolutely pancreas-specific.
    • Since E1 is stable during intestinal transit, the faecal elastase 1 concentration reflects the secretory capacity of the pancreas (diagnosis or exclusion of pancreatic exocrine insufficiency).
    • Digestive enzyme substitution therapy has no influence on the determination of E1. The monoclonal antibodies used in the test are monospecific for canine elastase 1, therefore recognizing only elastase 1 of canine origin. There is no cross-reaction with bovine or porcine elastases, contained in the preparations used for enzyme substitution therapy.
    • Substitution therapy does not need to be discontinued 5 days before measurement, in contrast to the determination of faecal chymotrypsin activity.
    • There is no need for a 12-hour starvation period, in contrast to the necessary preparation before the cTLI test.
    • The Quick-Prep™ stool sample extraction system is available also (Cat.-No. 09-Quick).

    Reference concentration

    Values above 40 µg/g faeces indicate normal pancreatic exocrine function.
    Values below 10 µg/g faeces indicate a severe pancreatic exocrine insufficiency.
    Borderline values („grey zone“) of 10 – 40 µg/g faeces suggest the beginning of pancreatic exocrine insufficiency.

    High specificity and sensitivity

    Determined for clinically manifest pancreatic insufficiency (Cut off < 10 µg/g)
    Specificity: 92% Sensitivity: 95%

    Method of detection

    Sandwich ELISA (96-well format) based on two monoclonal antibodies highly specific for canine pancreatic elastase 1.

    Sample material

    • A single pea-sized stool sample is sufficient.
    • High stability of pancreatic elastase 1 allows time for convenient mailing.
    • No need to interrupt digestive enzyme substitution therapy.

    Short protocol for the experienced user

    Important : The short protocol is not a substitute for the detailed protocol given in the instruction manual!

    • Prepare the sample-/washing buffer and the extraction buffer
    • Extract and homogenize faeces
    • Dilute faeces extract in sample-/washing buffer
    • Pipette 50 µl blank, standards, control and samples in duplicate into the ELISA-strips
    • Incubate 60 minutes at room temperature
    • Wash
    • Add 50 µl anti E1-bio (1:100)
    • Incubate 30 minutes at room temperature
    • Wash
    • Add 100 µl TMB substrate solution (ready-to-use)
    • Incubate 20 minutes at room temperature (in the dark)
    • Add 100 µl stop solution (ready-to-use)
    • Read plate at OD 450 or OD 450 – OD 620 between 5 and 30 minutes after addition of the stop solution
    • Evaluate with standard curve using a log-log scale

    Rapid Test

    Exocrine Pancreatic Insufficiency (EPI) is often underdiagnosed . The presenting symptoms
    are non-specific and may include:
    • Weight loss
    • Maldigestion
    • Diarrhoea
    • Vomiting
    • Poor coat condition

    Once diagnosed it can successfully be treated with pancreatic enzymes.

    ScheBo® • Pancreas Elastase 1 Quick™ Canine Test:
    • Diagnosis/exclusion of Exocrine Pancreatic Insufficiency caused by e.g. Pancreatic Acinar Atrophy, Chronic Pancreatitis,
    • Diabetes Mellitus, Pancreatic Cancer, etc.
    • Uses monoclonal antibodies – substitution therapy does not influence the test result
    • Absolutely pancreas-specific
    • No blood sampling
    • No starvation periods needed
    • Intestinal inflammation does not interfere with the result
    • High sensitivity and specificity

    Sample Material:

    • A single small stool sample
    • High sample stability allows storage at room temperature